Gut-derived molecule imidazole propionate may accelerate Alzheimer's pathology
Researchers identified the gut bacterial metabolite imidazole propionate as a factor that can weaken the blood-brain barrier and worsen Alzheimer’s-related protein changes.
Scientists have pinpointed imidazole propionate, a metabolite generated by specific gut bacteria, as a possible bridge between the microbiome and Alzheimer’s disease. The molecule originates from bacterial processing of the amino acid histidine, enters circulation, and can impair the blood-brain barrier, allowing it to reach neurons. Laboratory work demonstrated that the compound intensifies amyloid-beta plaque formation and increases tau phosphorylation, both central to neurodegeneration.
In a cohort of 1,196 cognitively normal adults, higher blood levels of imidazole propionate correlated with lower test scores and raised concentrations of pTau-217 and neurofilament light, markers of early brain damage. Parallel mouse studies confirmed that chronic exposure to the metabolite aggravated plaque deposition, tau abnormalities, and astrocyte activation. The authors suggest that targeting the metabolite itself, rather than the bacteria, could offer a therapeutic route similar to cholesterol-lowering drugs.
Why it matters
Linking a gut-derived chemical to Alzheimer’s progression opens new avenues for early detection and treatment.
In this story
